Abstract
Nadolol, 120 and 240 mg daily, reduced essential tremor in a placebo-controlled double-blind study. The effect was observed in patients who had previously responded to propranolol but not in those who had not benefited from propranolol therapy.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Clinical Trials as Topic
-
Double-Blind Method
-
Humans
-
Male
-
Middle Aged
-
Nadolol
-
Placebos
-
Propanolamines / administration & dosage*
-
Propanolamines / therapeutic use
-
Propranolol / therapeutic use
-
Tremor / drug therapy*
Substances
-
Placebos
-
Propanolamines
-
Nadolol
-
Propranolol